Azenta Inc
AZTA
Get informed when a big investor buys or sells
+ Follow
Current Fair Value
224.1% downsideOvervalued by 224.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.05 Billion |
|---|---|
| Enterprise Value | $922.13 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.22 |
| Beta | 1.43 |
| Outstanding Shares | 46,063,000 |
Return
| Return on Equity | -11.70% |
|---|---|
| Return on Assets | -9.55% |
| Return on Invested Capital | -0.97% |
Valuation & Multiples
| P/E Ratio | -5.92 |
|---|---|
| PEG | -1.99 |
| Price to Sales | 1.99 |
| Price to Book Ratio | 0.72 |
| Enterprise Value to Revenue | 1.55 |
| Enterprise Value to EBIT | -57.49 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0.11 |
| Debt to Equity | 0.07 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | 58,900▲ 4.25% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 116.13%▲ 2.19% |
|---|---|
| Total Invested | $1.13B▼ 35.30% |
| Investors Holding | 260▼ 34.00% |
ESG Score
No data
About Azenta Inc
3,159 employees
CEO: Stephen Schwartz Brooks Automation Inc. is a leading provider of life science sample-based solutions and semiconductor manufacturing solutions worldwide. The Company's Life Sciences business provides a full suite of reliable cold-chain sample management...
Relevant Senate Committees
This committee's analysis and official scoring of tax legislation directly shapes the corporate tax environment, capital investment credits, and overall fiscal policy, significantly impacting Azenta's profitability and its customers' R&D budgets.
As the primary tax-writing committee, it dictates corporate tax policy (influencing Azenta's profitability) and trade policy (critical for Azenta's global semiconductor operations). It also affects healthcare spending relevant to its life science customers.
This committee allocates federal discretionary spending. Its decisions on funding for scientific research (e.g., NIH, NSF) directly impact the budgets of Azenta's academic and biotech customers, affecting demand for its services.
This committee's oversight of the FDA and NIH directly impacts Azenta's life sciences division, influencing drug approval processes and funding for research institutions that are its customers.
This committee directly impacts Azenta through intellectual property protection (critical for both genomic technologies and semiconductor designs) and antitrust oversight, which affects the competitive landscape for its industries.
This committee has direct oversight of interstate commerce, science, and technology. It impacts the 'Big Tech' sector (where semiconductors are critical) through privacy and data laws (relevant for genomic services) and promotes scientific research.